Cryoviva
Cryoviva is an Indian umbilical cord blood and cord tissue stem cell bank serving expectant parents globally, with 300,000+ customers and operations across India, Southeast Asia, the Gulf, and East Africa.
- Company typePrivate
- Founded2006
- HeadquartersGurugram, India
- Headcount501–1,000
- GTM typeB2C
- OfferingServices
What Cryoviva does
Cryoviva Biotech Private Limited is an Indian umbilical cord blood and cord tissue stem cell bank founded in 2006 and headquartered in Gurgaon, Haryana. Operating as the healthcare vertical of the diversified RJ Corp conglomerate (parent of Varun Beverages and Devyani International), Cryoviva runs a 28,000 square-foot state-of-the-art processing and storage facility and serves more than 300,000 parent customers across India and international markets including Singapore, Thailand, Nepal, Vietnam, the UAE, Oman, and Bahrain.
The company's core offering is end-to-end stem cell banking — collection via proprietary closed-bag transfer kits at partner hospitals, processing using USFDA-cleared Sepax automated technology (FACT and AABB accredited, claimed to deliver up to 52% higher cell yield than open processing), and long-term cryogenic storage at -196°C. Beyond the Sepax platform, Cryoviva has developed a proprietary non-enzymatic Explant Technique for mesenchymal stem cell (MSC) processing that it positions as trade-secret-protected IP. The product portfolio spans four tiers (Super Saver, Saver, Blessing Plus, and premium Cryo Supra with ready-to-use MSCs), additional services including CFU Assay, HLA High Resolution typing, New Born Screening, Astro DNA testing, and Lifetime Storage, and two banking models: Family Banking (private dedicated storage) and Social Banking (a shared pool model designed to improve HLA matching probability).
Cryoviva generates revenue primarily through subscription contracts that bundle processing fees with multi-year (up to 21-year) storage fees, supplemented by one-time fees for ancillary services. The go-to-market is sales-led and direct-to-consumer, leveraging a pan-India network of 200+ cities and towns via OB-GYN referral partnerships, free home presentations, and customer referral programs. Distribution internationally is executed through wholly-owned subsidiaries (Singapore, Thailand, Nepal, Vietnam) and channel partners (UAE, Oman, Bahrain). The company holds a full stack of accreditations — AABB, CAP, ISO 9001:2015, NABL, DCGI, WHO GLP, and cGMP/SGS — positioning it as one of the most credentialed stem cell banks operating from India.
Cryoviva firmographics
Firmographics- Name
- Cryoviva
- Legal name
- Cryoviva Biotech Private Limited
- Website
- https://cryoviva.in
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Cryoviva is an Indian umbilical cord blood and cord tissue stem cell bank serving expectant parents globally, with 300,000+ customers and operations across India, Southeast Asia, the Gulf, and East Africa.
- Ownership category
- akta.pro rank
Cryoviva industry classification
Industry- Product category
- Stem Cell Banking Services
- NAICS
- Blood and Organ Banks (621991)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industries
- Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)
Keywords
Where Cryoviva is headquartered
LocationHeadquarters
- HQ city
- Gurugram
- HQ country
- India
- HQ region
- Asia
Offices8 records
Markets served
Cryoviva business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Stem Cell Banking Services: Cryoviva generates revenue through cord blood and cord tissue stem cell banking services. The company offers multiple product tiers (Super Saver, Saver, Blessing Plus, Cryo Supra) with both family banking and social banking options. Revenue comes from processing fees and storage fees over contract periods up to 21 years.
- Additional Services: Additional services including CFU Assay, HLA High Resolution typing, New Born Screening, Astro DNA testing, and Lifetime Storage options.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Blessing Plus - Cord blood banking with automated processing |
| Subscription | Annual | Saver - Cord blood and cord tissue stem cell preservation |
| Subscription | Annual | Super Saver - Basic cord blood stem cell banking |
| Subscription | Annual | Cryo Supra - Premium product with all best-in-class technologies including ready-to-use MSCs |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Cryoviva product offering
Product offeringCore offering
Cryoviva provides umbilical cord blood and cord tissue stem cell banking services for expectant parents. The company collects cord blood at the time of delivery, processes it using USFDA-cleared Sepax automated technology at its 28,000 sq ft facility in Gurugram, and cryogenically stores samples at -196°C for contract periods up to 21 years. Services span Family Banking (private storage) and Social Banking (shared pool model) options, supported by HLA typing and newborn screening add-ons.
Product overview
Cryoviva offers a comprehensive umbilical cord blood and cord tissue stem cell banking service through multiple product tiers. The core product portfolio includes Saver, Blessing Plus, Super Saver, and Cryo Supra - ranging from basic cord blood preservation to premium offerings with advanced MSC processing. Additional services encompass C.F.U. Assay, H.L.A. High Resolution, New Born Screening, Astro DNA, and Life Time Storage. The company provides two banking models: Family Banking (exclusive private storage) and Social Banking (shared pool with matching access). Key services include automated Sepax processing technology, proprietary Explant MSC processing, and professional collection and long-term storage facilities.
Differentiator
Problem solved
Functional benefit
Brands
- Super Saver: Product for preserving baby's cord blood stem cells at birth
- Saver
- Blessing Plus
- Cryo Supra
Products and services
- Family Banking
- Social Banking
- Collection Services
- Sepax Processing Service
- Explant MSC Processing Service
- Storage Services
- C.F.U Assay
- H.L.A High Resolution Typing
- New Born Screening
- Astro DNA
- Life Time Storage
Quantifiable outcome
- Sepax can harvest up to 52% more cell count compared to open processing method, enabling treatment of patients weighing up to 60kg vs 40kg from same cord blood unit
- +3 more outcomes
Companies that use Cryoviva
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Cryoviva technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cryoviva partnerships and signals
Strategic signalScale indicators7 records
Recent moves6 records
Expansion highlights5 records
Cryoviva competitors and assessment
Company assessmentDirect peers
- Smart Cells International: UK-headquartered private stem cell bank with international expansion in India and Middle East. Directly comparable on the Sepax processing platform, family banking pricing tiers, and the international-presence model Cryoviva aspires to.
- CBR (Cord Blood Registry) / CooperSurgical: Largest US private cord blood bank, now part of CooperSurgical. Sets global best-in-class benchmarks on Sepax technology, AABB standards, and direct-to-consumer marketing that Cryoviva benchmarks itself against.
- ReeLabs: Indian stem cell banking and processing company offering umbilical cord, menstrual blood, and adipose-derived stem cell banking. Competes with Cryoviva on price, technology positioning, and the same expectant-parent customer segment.
- StemCyte India Therapeutics: Operates both private and public cord blood banks in India with a focus on therapeutic-grade stem cell products. Direct competitor in social/community banking and in the advanced MSC product tier.
- LifeCell International: India's largest private stem cell and cord blood banking company; competes head-to-head with Cryoviva in family banking, has community stem cell bank (LifeCell Community), and offers similar service portfolio including HLA typing and CFU assays.
- Cordlife Group Limited: Singapore-listed (and India-domiciled Cordlife Sciences India) cord blood banking operator with multi-country presence across Asia. Direct competitor on processing technology, AABB accreditation, and pricing tiers in the Indian and Southeast Asian markets.
- ViaCord (Revvity): US-based family cord blood and cord tissue bank, now part of Revvity. Direct peer on premium MSC products, AABB accreditation, and USFDA-cleared processing. Comparable in product tiering and lifetime storage positioning.
- Cryo-Save / Esperite: European-headquartered family stem cell bank with historical presence in India. Direct peer in international expansion, family banking model, and biobanking regulatory standards.
Others
- Thermo Fisher Scientific (Cell Therapy Services): Provides cryopreservation media, controlled-rate freezers, and cell therapy manufacturing services used by cord blood banks including Cryoviva. Acts as an enabling technology and supply-chain peer rather than a direct competitor.
Regional players
- Cells4Life: UK-focused private cord blood and tissue bank with a regional concentration that limits direct India overlap, but uses the same Sepax platform and AABB-aligned processes; serves as a reference peer for technology and pricing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks4 records
Key highlights6 records
Customer concentration
Cryoviva social profiles
Digital presenceCryoviva compliance and trust
Trust signalCompliance6 records
Cryoviva financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cryoviva leadership team
Management profileNumber of profiles
Profiles6 records
Cryoviva subsidiaries and ownership
Company hierarchySubsidiaries4 records
Cryoviva funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cryoviva M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cryoviva
What does Cryoviva do?
Cryoviva provides umbilical cord blood and cord tissue stem cell banking services for expectant parents. The company collects cord blood at the time of delivery, processes it using USFDA-cleared Sepax automated technology at its 28,000 sq ft facility in Gurugram, and cryogenically stores samples at -196°C for contract periods up to 21 years. Services span Family Banking (private storage) and Social Banking (shared pool model) options, supported by HLA typing and newborn screening add-ons.
Is Cryoviva a public or private company?
Cryoviva is a private company. It is classified as corporate owned and is currently operating.
When was Cryoviva founded?
Cryoviva was founded in 2006. It employs 501 to 1,000 people.
Where is Cryoviva based?
Cryoviva is headquartered in Gurugram, India, in the Asia region.
How does Cryoviva make money?
Two revenue lines are on record. Stem Cell Banking Services are the primary driver. The others are additional Services.
Who are Cryoviva's main competitors?
Direct peers on record are Smart Cells International, CBR (Cord Blood Registry) / CooperSurgical, ReeLabs, StemCyte India Therapeutics, LifeCell International, Cordlife Group Limited, ViaCord (Revvity) and Cryo-Save / Esperite. Thermo Fisher Scientific (Cell Therapy Services) is listed as an others. Cells4Life is listed as a regional player.
Does Cryoviva have an API?
No public API is recorded for Cryoviva.
What industry is Cryoviva in?
Cryoviva's product category is Stem Cell Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAGAGAK, Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low). Its NAICS code is 621991 and its SIC code is 2836.